Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (271-280 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Leukemia|June 17, 2024
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2016
Myelomatous Involvement of the Central Nervous SystemJonas Paludo, Utkarsh Painuly, Shaji Kumar, et al.
Blood Cancer Journal|August 17, 2023
Long-term outcomes of allogeneic stem cell transplant in multiple myelomaWalker M Schmidt, Nirosha D Perera, Francis K Buadi, et al.
Leukemia|December 16, 2024
Capillary leak phenotype as a major cause of death in patients with POEMS syndromeKenzie Lee, Taxiarchis Kourelis, Marcella Tschautscher, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Leukemia|July 11, 2025
Interleukin-6 is a highly prognostic biomarker for POEMS syndromeJoselle Cook, Rahma Warsame, Maryam Omar, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Blood Advances|June 25, 2026
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System InvolvementAlexander Xiao, Saurabh S Zanwar, Yi Lin, et al.
Pageof 48

Showing results (271-280 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Leukemia|June 17, 2024
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2016
Myelomatous Involvement of the Central Nervous SystemJonas Paludo, Utkarsh Painuly, Shaji Kumar, et al.
Blood Cancer Journal|August 17, 2023
Long-term outcomes of allogeneic stem cell transplant in multiple myelomaWalker M Schmidt, Nirosha D Perera, Francis K Buadi, et al.
Leukemia|December 16, 2024
Capillary leak phenotype as a major cause of death in patients with POEMS syndromeKenzie Lee, Taxiarchis Kourelis, Marcella Tschautscher, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Leukemia|July 11, 2025
Interleukin-6 is a highly prognostic biomarker for POEMS syndromeJoselle Cook, Rahma Warsame, Maryam Omar, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Blood Advances|June 25, 2026
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System InvolvementAlexander Xiao, Saurabh S Zanwar, Yi Lin, et al.
Pageof 48